Media Spotlight
Proton therapy has been approved by the FDA as a form of cancer treatment for over 30 years. But does it provide any added benefit over photon therapy? Penn Center for Cancer Care Innovation (PC3I) Director Justin Bekelman, MD, discusses this ongoing debate and how to resolve it with Managed Healthcare Executive. The article elevates the nuanced, ongoing conversations around photon versus proton therapy for cancer treatment, specifically highlighting PC3I’s RadComp Study. The RadComp study, short for Radiotherapy Comparative Effectiveness, is currently comparing these two types of radiation therapies for the treatment of breast cancer.
Both photons and protons break down DNA within cancer cells, thus preventing those cells from replicating. Neither photon nor proton therapy is experimental. Both are on the cutting-edge of cancer therapy.
“What remains undefined is whether [proton beam therapy] is any better than what we currently use…. It is a proven treatment, but is it proven as better than what we usually do for the prevalent cancers? The answer is not yet,” Bekelman shared.
Bekelman also highlights an ongoing barrier to enrollment in clinical trials designed to answer these questions, saying, “There remains a gap in engagement across manufacturers, providers, insurers, and funders on how to pay for proton therapy treatments as part of large definitive randomized trials of this technology.”
Continue reading the full article at Managed Healthcare Executive.
Related News
Media Spotlight
PC3I Associate Director Lola Fayanju on Breast Cancer Screening Recommendations
09.27.2023
In an interview with the Philadelphia Inquirer, PC3I Associate Director Lola Fayanju commented on recently updated breast cancer screening recommendations.
Media Spotlight
Proton Therapy Study at Penn Medicine Gains New Attention
02.14.2023
As part of the RadComp study, Penn Medicine and over 20 radiation centers nationwide are comparing the effectiveness of photon therapy and proton therapy to treat breast cancer.
Media Spotlight
Machine Learning-Triggered Behavioral Nudges Quadrupled Serious Illness Conversation Rates
01.12.2023
A team led by PC3I Innovation Faculty Ravi Parikh has found that machine learning-triggered behavioral nudges quadrupled the rates of seriousness illness conversations for patients with advance cancer.